Resolves as YES if the annual cost of Lp(a)-reducing therapy drops below $1000 (US) in at least 4 of the following countries: USA, UK, France, Japan, India, Canada, Australia, Germany, Italy. Various factors such as discounts, generics, or insurance adjustments may contribute to the price reduction before January 1st, 2030. The therapy must achieve a reduction in Lp(a) levels by at least 70% to qualify.

Different years:

/RemNi/will-lpareducing-therapy-cost-less-qya2tff8vv (this question)

/RemNi/will-lpareducing-therapy-cost-less-t6hfyt9ntd

Different drugs:

/RemNi/will-semaglutide-cost-less-than-100-bcc4amzl8u

/RemNi/will-pcsk9-inhibitors-cost-less-tha-174rkp4gl7

/RemNi/will-lpareducing-therapy-cost-less-qya2tff8vv (this question)

Key Details:

• Price Measurement: The price considered will be the average annual cost for a standard dosage as prescribed for an adult patient.

• Verification: The price will be verified through publicly available data from reputable sources such as healthcare databases, insurance company formularies, or pharmaceutical company pricing information.

• Timeline: The market will resolve based on the prices available before January 1st, 2030.

Resolution Criteria:

• Yes: If by January 1st 2030, the average annual cost of Lp(a)-reducing therapy for a standard dosage is found to be less than $1000 in at least 4 of the specified countries (USA, UK, France, Japan, India, Canada, Australia, Germany, Italy), and the therapy achieves at least a 70% reduction in Lp(a) levels, this market will resolve to "Yes."

• No: If the price remains $1000 or higher in fewer than 4 of these countries, or if the therapy does not achieve at least a 70% reduction in Lp(a) levels, this market will resolve to "No."

Additional Information:

• The market takes into consideration any form of price reduction, including but not limited to discounts, generic versions, and insurance reimbursements, as long as the out-of-pocket cost to the patient averages less than $1000 per year.

• Adjustments for inflation or changes in standard dosage guidelines will not be factored into the resolution of this market.